DelveInsight's "Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rare NRG1 Fusion market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Rare NRG1 Fusion drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Rare NRG1 Fusion treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Rare NRG1 Fusion: An Overview
The neuregulin-1 (NRG1) gene encodes for the neuregulin 1, a growth factor belonging to the complex family of proteins also called heregulins. These proteins are structurally related to the stimulation of ERBB receptors tyrosine kinase activity and EGF signals. Specifically, the NRG1-receptor binding induces the phosphorylation of the intrinsic kinase domains of ERBB3 and stimulates its dimerization with the ERBB2 receptor and the activation of the downstream PI3K-AKT and MAPK pathways.
NRG1 fusions are a rare but powerful oncogene driver that makes cancer particularly aggressive and deadly when it is present. Therefore, they have emerged as a potential therapeutic target across multiple tumor types.
There are currently no approved treatments targeted toward treating cancers caused by NRG1 Fusions. The standard strategies for treating patients with advanced solid tumors that are NRG1 fusion–positive are chemo-immunotherapy or novel anti–PD-1 or anti–PD-L1 agents.
Rare NRG1 Fusion Market Key Facts
-
The therapeutic market of Rare NRG1 Fusion in the seven major markets is expected to increase during the study period (2019–2032) with a CAGR of 25.9%.
-
According to the estimates, the highest market size of NRG1 Fusion is found in the United States, followed by Japan.
-
The total market size of NRG1 Fusion therapies in the United States is expected to increase with a CAGR of 26.8% in the study period (2019–2032).
-
The total market size of NRG1 Fusion therapies in Japan is expected to increase with a CAGR of 26.1% in the study period (2019–2032).
-
In the year 2021, the total incident case of Rare NRG1 Fusion were 5,733 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
-
In the United States, the total number of incident cases of NRG1 Fusion was 2,122 cases in the year 2021 which is expected to grow during the study period, i.e., 2019–2032.
-
In the year 2021, the total incident cases of NRG1 Fusion in EU-5 were highest in Germany which are expected to grow during the study period, i.e., 2019–2032.
-
In Japan, the total number of incident cases of NRG1 Fusion was 1,201 cases in the year 2021 which is expected to grow during the study period, i.e., 2019–2032.
-
According to a study conducted by Russo et al. (2019) titled “NTRK and NRG1 gene Fusions in advanced non-small cell lung cancer (NSCLC)”, the reported incidence of NRG1 Fusions is of approximately 0.2–0.5% in unselected NSCLCs. To date, 18 different fusion partners for NRG1 have been reported in NSCLCs and the CD74-NRG1 fusion variant is the most common in NSCLCs.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Rare NRG1 Fusion market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Rare NRG1 Fusion market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Rare NRG1 Fusion Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Rare NRG1 Fusion epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Rare NRG1 Fusion Epidemiology, Segmented as -
-
Total Incident Cases of NRG1 Fusion in selected solid tumors in the 7MM from 2019 to 2032
-
Total Stage-specific Cases of NRG1 Fusion in the 7MM from 2019 to 2032
-
Total Treated cases of NRG1 Fusion in the 7MM from 2019 to 2032
Rare NRG1 Fusion Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Rare NRG1 Fusion market or expected to be launched during the study period. The analysis covers the Rare NRG1 Fusion market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Rare NRG1 Fusion market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the Rare NRG1 Fusion drugs based on their sale and market share.
The report also covers the Rare NRG1 Fusion pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Rare NRG1 Fusion Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market
Rare NRG1 Fusion Therapeutics Analysis
The pipeline of drugs for Rare NRG1 Fusion is quite weak as it possesses very few potential key players, such as Elevation Oncology and Merus. Additionally, Hummingbird Bioscience also has a lead candidate in the early stages of development. However, the dynamics of the market are anticipated to change in the coming years owing to the improvement in the research and development activities so that the market will comprise efficient treatment options. The launch of emerging therapies is expected in the near future.
Rare NRG1 Fusion Companies Actively Working in the Therapeutics Market Include
-
Elevation Oncology
-
Merus
-
Hummingbird Bioscience
-
Boehringer Ingelheim
-
AVEO Oncology
-
CANbridge Pharmaceuticals
-
Salubris Biotherapeutics
And Many More
Emerging and Marketed Rare NRG1 Fusion Therapies Covered in the Report Include:
-
MM-121/Seribantumab: Elevation Oncology
-
Zenocutuzumab/MCLA-128: Merus
-
HMBD-001: Hummingbird Bioscience
-
Tarloxotinib: Rain Therapeutics
-
AV-203/CAN017: CANbridge Pharmaceuticals/AVEO Oncology
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Rare NRG1 Fusion Competitive Intelligence Analysis
4. Rare NRG1 Fusion Market Overview at a Glance
5. Rare NRG1 Fusion Disease Background and Overview
6. Rare NRG1 Fusion Patient Journey
7. Rare NRG1 Fusion Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Rare NRG1 Fusion Treatment Algorithm, Current Treatment, and Medical Practices
9. Rare NRG1 Fusion Unmet Needs
10. Key Endpoints of Rare NRG1 Fusion Treatment
11. Rare NRG1 Fusion Marketed Therapies
12. Rare NRG1 Fusion Emerging Drugs and Latest Therapeutic Advances
13. Rare NRG1 Fusion Seven Major Market Analysis
14. Attribute Analysis
15. Rare NRG1 Fusion Market Outlook (In US, EU5, and Japan)
16. Rare NRG1 Fusion Access and Reimbursement Overview
17. KOL Views on the Rare NRG1 Fusion Market
18. Rare NRG1 Fusion Market Drivers
19. Rare NRG1 Fusion Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Chemotherapy Induced Nausea and Vomiting Market
"Chemotherapy Induced Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy Induced Nausea and Vomiting market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chemotherapy Induced Nausea and Vomiting market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
